Table 1 Characteristics of patients according to the treatment response

Age (years)

0.177

 <60

10 (76.9%)

9 (52.9%)

 ≥60

3 (23.1%)

8 (47.1%)

FIGO stage

0.030 *

 I~II

4 (30.8%)

12 (70.6%)

III~IV

9 (69.2%)

5 (29.4%)

Tumor size (cm)

0.020 *

 <4

1 (7.7%)

8 (47.1%)

 ≥4

12 (92.3%)

9 (52.9%)

LNs metastasis

0.153

 Negative

5 (38.5%)

11 (64.7%)

 Positive

8 (61.5%)

6 (35.3%)

Pre-NLR

0.009 *

 Low

1 (7.7%)

9 (52.9%)

 High

12 (92.3%)

8 (47.1%)

Pre-PNR

0.225

 Low

9 (69.2%)

8 (47.1%)

 High

4 (30.8%)

9 (52.9%)

Pre-PLR

0.004 *

 Low

4 (30.8%)

14 (82.4%)

 High

9 (69.2%)

3 (17.6%)

Pre-LMR

0.003 *

 Low

7 (53.8%)

1 (5.9%)

 High

6 (46.2%)

16 (94.1%)

10F-NLR

0.127

 Low

4 (30.8%)

10 (58.8%)

 High

9 (69.2%)

7 (41.2%)

10F-PNR

0.012 *

 Low

4 (30.8%)

13 (76.5%)

 High

9 (69.2%)

4 (23.5%)

10F-PLR

0.013 *

 Low

6 (46.2%)

15 (88.2%)

 High

7 (53.8%)

2 (11.8%)

10F-LMR

0.004 *

 Low

10 (76.9%)

4 (23.5%)

 High

3 (23.1%)

13 (76.5%)

Immune score, median (interquartile range)

0.042 (-0.264 to 0.278)

0.548 (0.416 to 0.749)

0.002 *